Profile data is unavailable for this security.
About the company
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
- Revenue in SEK (TTM)52.67m
- Net income in SEK-383.48m
- Incorporated1997
- Employees112.00
- LocationBioInvent International ABThe Gamma Building, Ideongatan 1LUND 223 70SwedenSWE
- Phone+46 462868550
- Fax+46 462110806
- Websitehttps://www.bioinvent.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nightingale Health Oyj | 49.44m | -198.10m | 1.47bn | 84.00 | -- | 2.34 | -- | 29.68 | -0.29 | -0.29 | 0.0723 | 1.37 | 0.0441 | 2.33 | 3.46 | 51,880.95 | -17.67 | -14.59 | -18.99 | -15.99 | 66.45 | 77.81 | -400.73 | -435.73 | 9.74 | -- | 0.0308 | -- | 4.21 | 16.13 | 3.43 | -- | 8.54 | -- |
Egetis Therapeutics AB (publ) | 82.00m | -295.80m | 1.55bn | 32.00 | -- | 3.37 | -- | 18.96 | -1.12 | -1.12 | 0.3106 | 1.37 | 0.1306 | 19.09 | 6.53 | 3,037,037.00 | -43.09 | -33.02 | -51.32 | -36.46 | 87.20 | -- | -329.88 | -357.72 | 1.55 | -28.66 | 0.2158 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
Nykode Therapeutics ASA | 63.69m | -392.81m | 1.61bn | 179.00 | -- | 1.02 | -- | 25.29 | -1.30 | -1.30 | 0.2053 | 4.98 | 0.0333 | -- | 1.59 | 379,635.90 | -20.57 | 5.65 | -23.15 | 6.38 | -- | -- | -616.79 | 18.13 | -- | -- | 0.0305 | -- | 79.99 | 282.17 | 17.75 | -- | 187.37 | -- |
Nanoform Finland Oyj | 26.03m | -245.79m | 1.62bn | 174.00 | -- | 2.01 | -- | 62.18 | -0.2707 | -0.2707 | 0.0285 | 0.829 | 0.0269 | 97.30 | 6.27 | 13,906.00 | -25.39 | -27.13 | -27.55 | -29.48 | -631.53 | -604.26 | -944.30 | -1,023.70 | 8.12 | -- | 0.0778 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
Cereno Scientific AB | 0.00 | -69.48m | 1.71bn | 5.00 | -- | 6.78 | -- | -- | -0.283 | -0.283 | 0.00 | 0.8998 | 0.00 | -- | -- | 0.00 | -23.45 | -16.81 | -25.41 | -18.26 | -- | -- | -- | -- | -- | -9.44 | 0.1519 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
Vicore Pharma Holding AB | 104.24m | -200.07m | 1.86bn | 28.00 | -- | 2.20 | -- | 17.88 | -1.76 | -1.76 | 0.9134 | 3.79 | 0.2546 | -- | 64.15 | 4,343,459.00 | -48.87 | -58.65 | -53.82 | -65.58 | -- | -- | -191.92 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
Solar Foods Oyj | 196.48k | -121.26m | 2.06bn | 40.00 | -- | 6.45 | -- | 10,476.18 | -0.4438 | -0.4438 | 0.0007 | 1.15 | 0.0004 | -- | 0.0049 | 558.71 | -21.32 | -- | -24.11 | -- | 20,183.14 | -- | -61,719.29 | -- | -- | -2.71 | 0.4266 | -- | -- | -- | -66.44 | -- | -- | -- |
Devyser Diagnostics AB | 196.00m | -54.20m | 2.19bn | 127.00 | -- | 5.93 | -- | 11.16 | -3.33 | -3.33 | 12.05 | 22.35 | 0.3855 | 1.61 | 5.42 | 1,661,017.00 | -10.68 | -8.97 | -12.15 | -10.15 | 83.11 | 80.14 | -27.70 | -23.91 | 4.01 | -- | 0.1498 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
Hansa Biopharma AB | 163.56m | -801.64m | 2.82bn | 146.00 | -- | -- | -- | 17.25 | -14.59 | -14.59 | 2.96 | -3.23 | 0.1368 | 40.48 | 1.43 | 973,589.30 | -67.03 | -47.96 | -88.36 | -56.12 | 42.86 | 64.18 | -490.11 | -835.04 | 3.04 | -9.32 | 1.29 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
BioInvent International AB | 52.67m | -383.48m | 2.89bn | 112.00 | -- | 2.63 | -- | 54.85 | -5.83 | -5.83 | 0.8001 | 16.68 | 0.0377 | -- | 0.8604 | 474,495.50 | -27.41 | -17.50 | -29.50 | -18.64 | -- | -- | -728.09 | -131.63 | 12.18 | -- | 0.0171 | -- | -78.09 | 13.14 | -677.13 | -- | 28.17 | -- |
Data as of Oct 11 2024. Currency figures normalised to BioInvent International AB's reporting currency: Swedish Krona SEK
Holder | Shares | % Held |
---|---|---|
Redmile Group LLCas of 31 Dec 2023 | 10.13m | 15.39% |
HBM Partners AG (Investment Management)as of 31 Dec 2023 | 5.08m | 7.71% |
Fj�rde AP-fondenas of 31 Dec 2023 | 4.02m | 6.11% |
Handelsbanken Fonder ABas of 31 Jul 2024 | 1.69m | 2.56% |
E. �hman J :or Fonder ABas of 31 May 2024 | 622.60k | 0.95% |
Rhenman & Partners Asset Management ABas of 30 Jun 2023 | 450.00k | 0.68% |
SEB Investment Management ABas of 28 Jun 2024 | 344.25k | 0.52% |
Skandia Investment Management ABas of 31 May 2024 | 325.96k | 0.50% |
FCG Fonder ABas of 31 Dec 2023 | 167.78k | 0.26% |
Dimensional Fund Advisors LPas of 28 Jun 2024 | 52.27k | 0.08% |
More ▼
Data from 29 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.